The evolution of cancer is a Darwinian process, the composition of cancer cell population varying with time, especially after chemotherapy. Such changes occurring in the genetic landscape of tumours are possibly responsible for the chemotherapeutic resistance. Due to the recent advances in single cellular sequencing, the evolution of cancers can be monitored at the single cellular resolution. We reanalysed a previously published dataset composed of single cell RNAseq data, collected before, during and after the establishment of Paclitaxel tolerance, to identify single cell heterogeneity. We used gene expression analysis, gene expression rank correlation analysis, pathway analysis and mutation analysis to identify within group variations of cancer cells after chemotherapy. We identified a decrease in cancer cell within group diversity during the transition to drug-tolerance. Additionally, we observed high mutation rate in stressed single cells, which suggests genetic instability of cancer cells that could ultimately result in the development of drug resistance. Our analysis carries significant implications for developing personalised and efficient therapeutics against cancer.
Background
As a consequence of accumulated abnormalities in multiple cell regulatory systems, cancer cells exhibit unrestrained cell proliferation, compared to their normal counterparts. The goal of chemotherapy is to induce tumour cell death by targeting cell death pathways, such as apoptosis (e.g., Inhibitors of histone deacetylases), necrosis (DNA alkylating agents, Apoptolidin), mitotic catastrophe (e.g., Paclitaxel, Vincristine), autophagy (e.g., Tamoxifen) and senescence (e.g., Telomerase inhibitors) (Hannun, 1997; Ricci and Zong, 2006) . These interventions have proven to be successful in initial killing cancerous tumours. Nevertheless, cancer patients often experience recurrence, due to the development of therapeutic resistance. Cancer drug resistance, a major predicament in cancer therapy, is chiefly attributed to the intra-tumour heterogeneity of cancerous tumours (Dexter and Lith, 1986) .
Genomic processes causing an elevated rate of somatic mutations in cancer cells ultimately generate intra-tumour heterogeneity. Although the individual cells in a tumour mass originate from a single common ancestor, they continue to diverge, accruing cellspecific genetic differences (Burrel and Swanton, 2014) . As the cancer progresses, the individual cells accumulate genomic alterations (e.g., copy number variations, translocations, point mutations and epigenetic events), ultimately creating a diverse pool of cancer cells. Additionally, external factors (pH, hypoxia, mutagens) may elevate the rate of cellular diversification (Alfarouk et al., 2015) . When a chemotherapeutic agent is applied to target a specific cell apoptotic pathway, it creates a stringent directional selection pressure. As a result, pre-existing drug-resistant sub clones in the initial cell population survive the treatment, leading to chemotherapeutic resistance (Burrel and Swanton, 2014) . Evidence for tumour heterogeneity comes from histological observations (Komaki et al., 2006) , transcript expression (Bachtiary et al., 2006) , single nucleotide polymorphisms (Khalique et al., 2007) and large-scale genomic analysis of tumour sections to identify tumour sub populations (Navin et al., 2010) . Such population-based bulk sequencing analyses provide major insights into cancer genomics, but often fail to provide the insights at the cellular resolution that is crucial for understanding the tumour recurrence mechanisms after anti-cancer treatments (Wills and Mead, 2015) .
The advent of single cell sequencing provides a powerful new approach to study the genomic and transcriptomic basis of genetic alterations in individual cells. The single-cell exome and RNA-seq methods have made significant progress, rapidly overcoming many of the initial technical challenges (Navin, 2014) . Single cell sequencing aims to identify the dissimilarities between the cells that are considered to be homogeneous and untangle the complex hierarchal organisation in the clonal population of the tumour tissue. Identification of single cell expression profiles has uncovered complicated mechanisms in cellular development including clonal evolution, invasion, and metastatic dissemination (Jaitin et al., 2014; Guo et al., 2015; Navin, 2015; Gawad et al., 2016) . For instance, in lung adenocarcinoma xenograft tumour cells, a KRAS (G12D) single nucleotide variant showed a significant survival in vitro, providing an experimental model to predict treatment outcome (Kim et al., 2015) . Moreover, single cell sequencing methods have a potential role in clinical applications, to analyse scarce clinical samples and predict the resistance to chemotherapy by calculating tumour-diversity indices (Almendro et al., 2014) .
Cancer progression is accompanied by both spatial (between tumours and tumour regions) and temporal (at different tumour stages) heterogeneity. Therefore, to understand the evolution of drug resistance, sequencing multiple samples of single cells at different time points is crucial. Single cell sequencing studies often examine 1-2 time points (e.g., before and after chemotherapy, (Kim et al., 2015; Eirew et al., 2015; Melchor et al., 2014; Lee et al., 2014 ), yet increasing the sampling frequency evidently provides a better picture of emergence of resistance. In a recent study, Lee et al. (2014) performed single cell RNAseq on three groups of cells from the human breast carcinoma cell line, MDA-MB-231, 1) untreated cells, 2) stressed cells that had been exposed to paclitaxel treatment for five days and 3) drug-tolerant cells from a clonal population of cells that resumed proliferation after paclitaxel treatment (Lee et al., 2014) . Paclitaxel is a chemotherapy drug widely used to treat advanced and metastatic breast cancer (Bauer et al., 2010) . By targeting microtubules to interfere with the mitotic spindle, Paclitaxel causes cell cycle arrest and eventually apoptosis. Many patients show resistance to Paclitaxel, possibly through a wide variety of resistance mechanisms (Yusuf et al., 2003) . Single cell sequencing revealed that specific transcriptional programs are enacted within untreated, stressed, and Paclitaxel tolerant cell groups, generating high heterogeneity between single cells. Gene expression profiles of drug-tolerant cells were similar to untreated cells, and the population ultimately reacquired paclitaxel sensitivity. The analysis indicates that the drug tolerance was possibly achieved through the accumulation of transcriptional errors. However, the variation of cell heterogeneity during the development of resistance and the functional consequences of single cell-specific mutations remained unresolved.
Herein we reanalyse the Lee et al. (2014) dataset to identify accumulation of between cell differences during the progression of cancer (Lee et al., 2014) . Specifically, we examine the within group variation in gene expression and single nucleotide variations (SNVs; the number of variations and functional significance) to identify the heterogeneity of cancer cells during the development of paclitaxel resistance. We hypothesise that the between cell variation decreases during the development of resistance, because only a portion of diverse cells carries the ability to resist Paclitaxel either via transcriptome plasticity or existing mutations. We discuss the implications of decreased cell diversity in terms of resistance mechanisms and development of novel therapeutics.
Materials and methods

Data description
The initial raw sequence data was retrieved from the European Nucleotide Archive in fastq format (https://www.ebi.ac.uk/ena/data/view/SRP040309). See Lee et al. (2014) for a detailed description of treatment groups and sequencing (Lee et al., 2014) .
The data comprised of RNA sequence reads of 15 single cell samples and four bulk samples, sequenced from breast cancer cell-line MDA-MB-231, using Illumina HiSEq 2000. The single cell samples contained RNAseq reads of five untreated cancer cells, five stressed cells sequenced after the paclitaxel treatment, and five drug-tolerant cells that are sequenced from clones which continued to proliferate, after the treatment of paclitaxel. The bulk reads contained an untreated control cell population, a stressed population and two replicates of drug-tolerant population.
Data processing
The analysis pipeline is presented in Figure 1 . In order to prepare the data for the sequence analysis, the initial raw sequence data in the fastq format was processed by trimming the first nine bases from the 5'-end by removing the adapter sequences using Cutadapt (Martin, 2011) and TrimGalore (Krueger, 2016) . The processed reads were mapped to the human hg19 reference genome using STAR sequence aligner (Dobin et al., 2013) . Later, based on the RefSeq gene annotation of hg19, the gene-based expression levels were calculated using HTSeq (Anders et al., 2015) and normalised by RPKM conversion. obtained from the European Nucleotide Archive. Then the reads were trimmed, mapped and annotated to obtain raw read counts. DESeq2 was used to do the differential expression analysis. After normalising the read counts by RPKM conversion, rank based correlation analysis and PCA was carried out. Pathway analysis was carried out using highly expressed genes. Variants were identified by SAMtools and annotated by ANNOVAR and ingenuity variant analysis (see online version for colours)
Differential expression analysis
Differential Expression Analysis was performed on raw expression counts using DESeq2 (Love et al., 2014) . Comparisons were made between the treatment groups of single cell samples (Single cell control vs. drug tolerant, Single cell control vs. stressed, Single cell stressed vs. drug tolerant), treatment groups of single cell samples and bulk control sample (Bulk control vs. drug tolerant, Bulk control vs. stressed, Bulk control vs. Single cell control), and pairwise between each stressed and drug-tolerant single cell samples and single cell control (Single cell control vs. each single cell stressed samples, Single cell control vs. each single cell drug-tolerant samples). Differentially expressed genes were identified after a correction for false discovery rate (FDR 0.05).
Gene expression rank based correlation analysis
Based on the expression level (i.e., RPKM counts) of the genes in each sample, the genes were ranked and then the ranks were log transformed. To understand the correlation of expression level for the genes, the rank of each gene was compared separately between each pair of samples and the R 2 values were calculated. Thereafter, the R 2 values were combined based on the treatment groups and plotted to show the variation. To identify the clustering of the samples we carried out principle component analysis (PCA) using the gene ranks. The loadings of the principle components (PCs) that explains >90% of the variant was plotted to identify within and between group variations.
Pathway analysis
Pathway-based functional enrichment analysis was carried out for the highly expressed genes in the top 10 percentile of each sample using highly curated NCI pathway interaction database (Schaefer et al., 2009 ). For each sample, the KEGG pathways were filtered using the P value cutoff, P < 0.05. Later, based on the presence and the absence of pathways, they are converted to binary format, where the presence of pathway indicates 1 and absence indicates 0. To gain a better insight into the correlation of the cells at functional level especially in stressed and drug-tolerant cells, we categorised the pathways that are present in all the cell of stressed and drug-tolerant groups and clustering was performed.
Mutation analysis
SNV calling was performed on the preprocessed and the aligned.bam files using SAMtools mpileup function (Li et al., 2009 ). The variant was filtered out by applying quality filters, variant quality > 20 and Depth > 100. ANNOVAR (Wang et al., 2010 ) was used to identify and annotated exonic variants. Variant-specific functional inference such as the gain of function and loss of function mutations were identified using ingenuity variant analysis application (www.ingenuity.com/products/variant-analysis). Additionally, causally consistent low-frequency cancer driver variants were identified using Ingenuity knowledgebase of human pathology. The number of variants was analysed separately for each sample and then the number of variants shared within each treatment group was calculated.
Results
Differential expression analysis
A count table of approximately 26,000 genes was used for the DESeq2 differential expression analysis. Each single cell treatment group was compared against single cell control and bulk control (Figure 2(a) and (b) ). When differential expression analysis was carried out using both single cell and bulk control, stressed single cells had fewer differentially expressed genes than drug-tolerant cells (Figure 2(a) and (b) ). Many genes were differentially expressed in single cell drugtolerant cells compared to the single cell stressed cells (Figure 2(a) ). Significant differences in gene expression were observed between bulk control and single cell control (Figure 2(b) ).
We carried out pairwise comparisons, between each individual stressed and drugtolerant single cells and pooled single cell control cells. In terms of the number of differentially expressed genes, stressed single cells were more diverse than drug-tolerant single cells ( 
Gene expression rank based correlation analysis
Gene rank based correlation analysis was carried out to associate the expression rank of each gene between samples. The single cells in the control group showed the lowest R 2 value and the highest variation (Figure 4(a) ). The R 2 value stressed cells were higher compared to control. Drug-tolerant cells had the best correlation and the lowest within group variation. Both stressed and tolerant groups were significantly different from the control (P = 0.049 and P = 0.000, respectively). There was no significant difference between stressed and tolerant groups (P = 0.839, 95% confidence).
For the between group comparison, the single cells in stressed and tolerant groups were compared with both bulk and single cell controls. The stressed cells showed the highest variance and the highest R 2 value, compared to both bulk and single cell controls (Figure 4(a) ). Drug-tolerant cells, on the other hand, showed a lower variation and lower R 2 Value, when compared with the control (Figure 4(a) ). PC1 and PC2 explained > 90% variation. Drug tolerant and control single cells clustered together along PC1 and PC2 ( Figure 5 ). Single cell stressed and control showed higher within group variation compared to single cell drug tolerant along PC1 and PC2 (Figure 6(a) and (b) ).
Pathway analysis
Pathway-based functional enrichment analysis was used to identify the significantly enriched pathways for the highly expressed genes. Single cells were clustered based on the shared enriched pathways to identify the within and between treatment group similarities. In general, untreated control cells showed the least clustering in terms of enriched pathway profiles (Figure 7 ). 
Mutation analysis
Interestingly, stressed single cells showed the most diverse SNV profile, while the drugtolerant cells were the least diverse (Figure 8(a) ). Similarly the number of loss of function mutations, gain of function mutations and cancer driver mutations were the highest in stressed cells. These cells also had the lowest percentage of shared mutations (Figure 8(b)-(d) ). Drug-tolerant cells, on the other hand, carried many shared mutations, the percentage of shared mutations (driver mutations, loss of function and gain of function mutations) being twice as much as that of stressed cells (Figure 8(b)-(d) ). The number of within group shared mutations was normalised using total within group unique mutations, to avoid the bias of total mutations in each group (Normalised shared mutations = (within group shared mutations/within group unique mutations) × 100). Despite the low number of SNVs, tolerant cells still had the highest number of shared mutations (Normalised shared mutations: Driver mutations: single cell control 6.6%, single cell stressed 4.3%, single cell drug tolerant 10.9%, Gain of function mutations: single cell control 1.3%, single cell stressed 0.9%, single cell drug tolerant 3.9%, Loss of function mutations: single cell control 2.6%, single cell stressed 1.5%, single cell drug tolerant 3.0%). 
Discussion
Many cancers exhibit intra-tumour heterogeneity, confounding clinical diagnosis and targeted therapy of cancer (Burrel and Swanton, 2014) (Navin, 2014) . Such heterogeneity can cause the development of chemotherapeutic resistance, further challenging the use of chemotherapeutics (Dexter and Lith, 1986) . Therefore, recent studies of therapeutic resistance investigate the cancer evolution and the development of genetic differences at the single cell resolution (Navin, 2014) . During past few years, the rapid advancement of single cell sequencing has provided extensive datasets to enable uncovering of hidden mechanistics of cancer evolution. Several studies have investigated the single cell genetic alterations before and after drug treatments (Kim et al., 2015; Almendro et al., 2014; Eirew et al., 2015; Melchor et al., 2014; Lee et al., 2014) . Once such study by Lee et al. (2014) attempted temporal sampling of MDMD-231 single cells, during the course of disease progression, to identify the transcriptional heterogeneity of Paclitaxel tolerance (Lee et al., 2014) . We sought to re-analyse their data to emphasise the differences in genomic and transcriptomic diversity during the evolution of resistance. Compared to the bulk/population sequences, single cell RNAseq libraries had a higher sequencing depth at the cost of reduced genomic coverage (Lee et al., 2014) . This demonstrates that few single cells do not capture the complexity of the cancerous tumour (Figure 2(a) and (b) ). Therefore, when calculating differential expression we compared each treatment group separately with single cell control and the bulk control. Compared with the controls, the drug-tolerant cells showed the highest number of differentially expressed genes demonstrating that the cell population undergoes drastic genetic alterations during the process of developing drug resistance. As Paclitaxel causes cell apoptosis by interfering with microtubules formation, accumulation of mutations that counteract with microtubule damage may correspond to the development of Paclitaxel resistance. Indeed Li et al. (2014) identified that stressed cells have down-regulation of genes involved in maintenance of chromatin architecture, microtubule motor activity, mitosis, DNA repair, mRNA splicing, mRNA polyadenylation, and chromatin binding and up-regulation of genes in cell-cell adhesion and signalling, stress-induced response, apoptosis, glycolysis, amino acid biosynthesis, translation, protein folding and protein modification (Lee et al., 2014) . Interestingly, the authors found that the drug-tolerant cells showed the reverse trend with up-regulation of genes involved in microtubule motor activity, microtubule binding and protein kinase activity and down-regulation of involved in mRNA splicing, mRNA transcription factor activity, translation and cell adhesion.
We show that the within group variation of gene expression (i.e., in terms of the number of differentially expressed genes, Figure 3 and gene expression rank based correlation analyses, Figures 4-7) is decreasing during the course of resistance progression. Control cells represent a diverse population. As they become stressed and drug tolerant, only the cells that are capable of activating specific gene expression profiles survive (Figure 4) . As a result, the within group diversity of cells lessen after drug treatment. Li et al. (2014) observed distinct gene expression patterns in long-term stressed cells that were not apparent in drug-tolerant cells. Our findings elaborate theirs, providing a glimpse of the change in cancer cell heterogeneity, during drug treatment. Having a diverse cell population is crucial for a cancer to survive against strong and prolong chemotherapeutic treatments. This extraordinary heterogeneity of cancer cell populations has been documented by previous single cell RNAseq studies (Kim et al., 2015; Almendro et al., 2014; Eirew et al., 2015; Melchor et al., 2014; Patel et al., 2014) .
For instance, it has been shown that cells of individual glioblastoma tumours express various clinical expression subtypes within the same tumour, emphasising the need of novel tumour sub type classification systems (Patel et al., 2014) . The expressed sub types ranged from stem cell-like to fully differentiated suggesting that the stem-like cells may contribute to the generation of diverse genomics characteristics between individual cancer cells. These cancer stem cells carry the ability to the activate self-renewal pathways and known to be more resistant to a current therapeutics (Eyler and Rich, 2008) . The evolution of clusters of sub-clonal populations within tumours has been tracked over time, showing the evolution of tumours under different selection pressures (Burrel and Swanton, 2014) . Clonal architecture at disease relapse has been shown to be different from original and derive from either major or minor sub-clones (Anderson et al., 2011) .
Single cell RNAseq enables identification of low-abundance mutations that are responsible for the development of resistance. Li et al. (2014) identified unique SNVs in drug-tolerant cells corresponding to microtubule stabilisation. We sought to identify functional significance of mutations. Specifically, we carried out mutation analysis to further identify the differences within control, stressed and drug-tolerant cells, categorising the mutations based on their function (Gain of function, loss of function and driver mutations). Surpassing the control cells, stressed single cells accumulated a wide variety of mutations, many of them unique to the individual cells (Figure 8 ). Drugtolerant cells, on the other hand, showed the least mutational diversity (i.e., twice as much as shared mutations compared to the control and stressed cells), implying that only a specific set of mutations, possibly corresponding to repair the Paclitaxel induced damage and gain cancerous stage, is acquired at the stressed stage enables resistance. This observation agrees with the findings of Li et al. (2014) . For instance, the shared gain of function mutations in the drug-tolerant cells were located in the genes corresponding to chromatin assembly (e.g., HJURP) and cancer signalling pathways (e.g., TGF beta pathway, ACVR1), while shared loss of function mutations were located at genes involved in cellular apoptosis (e.g., HSPA9, LMNA, ANK1, UNC13D). Phylogenetic methods have revealed that mutations in cancer cells occur as 'punctuated burst' followed by stable clonal expansions (Navin et al., 2011) . Such bursts may be facilitated by administration of chemotherapy. For instance, in AML and glioma, chemotherapy has been found to cause mutagenesis (Ding et al., 2012; Johnson et al., 2014) . Specifically, acquisition of genome instability through DNA damaging therapies could lead to therapeutic resistance.
The abundance of SNVs in stressed cells could be also due to the increase of transcriptional errors occurring during the cellular stress (Lee et al., 2014) . Increased accumulation of functionally active mutations (i.e., Loss of function, Gain of function and cancer driver mutations) may enable the stressed cells to acquire drug tolerance. Driver mutations located in oncogenes and tumour suppressor genes support the cancer progression by conferring selective advantages to the cancer cell. Increased number of driver mutations has been observed in drug treated vs. untreated patient samples, due to the increase in subclonal complexity (Landau et al., 2013) . This suggests that the chemotherapeutic treatments may select for more aggressive clones following the therapeutic targeting of dominant, less aggressive clones.
Overall, the development of Paclitaxel resistance in MDMB-231 cells can be attributed to 1) selection of pre-existing resistant sub clones (i.e., cancer stem cells) and 2) de novo acquisition of resistant mutations (Burrel and Swanton, 2014) . Our gene expression analysis supports the selection hypothesis (Decrease of within group variation during the course of resistance development) while the mutation analysis suggests the possibility of de novo acquisition of mutations upon drug treatment. Essentially, as both hypotheses are not mutually exclusive, it is possible that cancer resistant cells (e.g., stem cells) get selected during the drug treatment and their genetic instability gives rise to genetically diverse individual cells (Brooks et al., 2015) . As the Paclitaxel resistance is known to be reversible (Lee et al., 2014) , such genetic plasticity is crucial to re-establish drug sensitivity. Nevertheless, it should be noted that few single cells do not represent the population level heterogeneity and therefore likely to underestimate intra-tumour genetic heterogeneity. Increased sampling effort is needed to fully understand the connection between drug resistance and the intra-tumour heterogeneity.
Conclusions
In summary, we re-analysed the single cell RNAseq data originally collected by Lee et al. (2014) , to better understand accumulation of between cell differences during the progression of Paclitaxel resistance (Lee et al., 2014) . As hypothesised, the between cell variation decreased during the development of resistance, but stressed cells showed an increased number of active mutations. This is attributed to the selection of genetically plastic cells in the original tumour during the drug treatment. Identification of the relevance of intra-tumour heterogeneity has important consequences for personalisedmedicine. For instance, the major tumour sub populations and the accumulated de novo mutations may vary between patients. Functional annotation of these unique variations could be used to predict the development of resistance in individual patients and possibly provide personalised treatment options to prevent the development of resistance. Alternatively, identification of mutations in the resistant population may enable prescription of secondary drugs to successfully tackle the resistant tumour populations (i.e., drug combination therapies). Moreover, evaluating the diversity of tumour population during disease progression may enable identification of 'tumour divers'. Ultimately, the therapeutics can be targeted against the drivers to effectively minimise the possibility of cancer recurrence.
